BACKGROUND: The mechanisms of tumor progression in mycosis fungoides (MF) and Sézary syndrome (SS) are poorly understood. Twist, a transcription factor, is thought to promote solid tumor progression by blocking p53 and inhibiting c-myc-induced apoptosis. Whether Twist expression is correlated to MF/SS stages remains unknown. METHODS: Twist, c-myc and p53 proteins in 68 MF/SS lesions across all T stages were examined by immunohistochemistry, and mRNA levels in peripheral blood CD4+ T-cells from SS patients were measured by real-time quantitative polymerase chain reaction. RESULTS: Positive staining for Twist was found in 12.5% (2/16) of T1 and 33.3% (7/21) of T2 early stage patches/plaques compared to 50.0% (9/18) of T3 tumors and 84.6% (11/13) of T4 erythroderma. Most T4 erythroderma were positive for Twist in dermal lymphocytes, with the strongest staining. Positive staining for c-myc was higher in T3/T4 lesions (29/31, 93.5%) than T1/T2 lesions (25/37, 67.6%, p < 0.05), with strongest staining in T3 tumors. Aberrant p53 expression was more common in T3/T4 lesions (8/31, 25.8%) than in T1/T2 lesions (2/37, 5.4%, p < 0.05). Twist mRNA was detected in all CD4+ T cells from SS patients but not in normal donors. CONCLUSIONS: Increased Twist protein expression in advanced MF/SS lesions suggests that Twist expression may correlate with MF/SS stages.
BACKGROUND: The mechanisms of tumor progression in mycosis fungoides (MF) and Sézary syndrome (SS) are poorly understood. Twist, a transcription factor, is thought to promote solid tumor progression by blocking p53 and inhibiting c-myc-induced apoptosis. Whether Twist expression is correlated to MF/SS stages remains unknown. METHODS:Twist, c-myc and p53 proteins in 68 MF/SS lesions across all T stages were examined by immunohistochemistry, and mRNA levels in peripheral blood CD4+ T-cells from SS patients were measured by real-time quantitative polymerase chain reaction. RESULTS: Positive staining for Twist was found in 12.5% (2/16) of T1 and 33.3% (7/21) of T2 early stage patches/plaques compared to 50.0% (9/18) of T3 tumors and 84.6% (11/13) of T4 erythroderma. Most T4 erythroderma were positive for Twist in dermal lymphocytes, with the strongest staining. Positive staining for c-myc was higher in T3/T4 lesions (29/31, 93.5%) than T1/T2 lesions (25/37, 67.6%, p < 0.05), with strongest staining in T3 tumors. Aberrant p53 expression was more common in T3/T4 lesions (8/31, 25.8%) than in T1/T2 lesions (2/37, 5.4%, p < 0.05). Twist mRNA was detected in all CD4+ T cells from SS patients but not in normal donors. CONCLUSIONS: Increased Twist protein expression in advanced MF/SS lesions suggests that Twist expression may correlate with MF/SS stages.
Authors: George Z Cheng; Wei Zhou Zhang; Mei Sun; Qi Wang; Domenico Coppola; Mena Mansour; Li Mei Xu; Carliann Costanzo; Jin Q Cheng; Lu-Hai Wang Journal: J Biol Chem Date: 2008-03-19 Impact factor: 5.157
Authors: Maarten H Vermeer; Remco van Doorn; Remco Dijkman; Xin Mao; Sean Whittaker; Pieter C van Voorst Vader; Marie-Jeanne P Gerritsen; Marie-Louise Geerts; Sylke Gellrich; Ola Söderberg; Karl-Johan Leuchowius; Ulf Landegren; Jacoba J Out-Luiting; Jeroen Knijnenburg; Marije Ijszenga; Karoly Szuhai; Rein Willemze; Cornelis P Tensen Journal: Cancer Res Date: 2008-04-15 Impact factor: 12.701
Authors: Bernice M Benoit; Neha Jariwala; Geraldine O'Connor; Landon K Oetjen; Timothy M Whelan; Adrienne Werth; Andrea B Troxel; Hélène Sicard; Lisa Zhu; Christopher Miller; Junko Takeshita; Daniel W McVicar; Brian S Kim; Alain H Rook; Maria Wysocka Journal: Arch Dermatol Res Date: 2016-10-20 Impact factor: 3.017
Authors: Liesbeth Hameetman; Leslie van der Fits; Willem H Zoutman; Jacoba J Out-Luiting; Gregg Siegal; Iwan J P de Esch; Maarten H Vermeer; Cornelis P Tensen Journal: Oncotarget Date: 2015-10-13
Authors: Alexandra Ion; Iris Maria Popa; Laura Maria Lucia Papagheorghe; Cristina Lisievici; Mihai Lupu; Vlad Voiculescu; Constantin Caruntu; Daniel Boda Journal: Dis Markers Date: 2016-10-16 Impact factor: 3.434